This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Serum Tissue Factor Level in Lung Cancer Patients as a Prognostic Factor

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2005 by National Taiwan University Hospital.
Recruitment status was:  Recruiting
Information provided by:
National Taiwan University Hospital Identifier:
First received: November 21, 2005
Last updated: March 13, 2006
Last verified: June 2005
This study uses serum tissue factor and tissue factor inhibitor and factor VII to monitor the pre-coagulation status in lung cancer patients and to correlate the pre-coagulation status with clinical staging and prognosis.

Lung Cancer

Study Type: Observational
Study Design: Allocation: Random Sample
Observational Model: Natural History
Time Perspective: Cross-Sectional
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by National Taiwan University Hospital:

Estimated Enrollment: 200
Study Start Date: June 2005
Detailed Description:

The staging of lung cancer was according to tumor size, involvement of lymph node and metastatic status. But there is a different prognosis in cancer patients of the same stage. The coagulation status of cancer patients was considered as an important possible prognostic factor. So in this study, we want to evaluate patients' coagulation status and find the relation of coagulation status and cancer status.

We thus propose a prospective study using coagulation factors in order to search for the relationship between cancer stage and pre-coagulation status in Taiwanese lung cancer patients. We will also evaluate the potential use of tissue factor as a prognosis predictor in lung cancer patients.


Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with newly-diagnosed lung cancer
  • Serum from cancer-free healthy volunteers

Exclusion Criteria:

  • Chronic renal failure or end-stage renal disease [ESRD] (creatinine [Cr] > 2 )
  • Hyperlipidemia on statin therapy
  • Acute myocardial infarction
  • Tapal or Plavix use
  • Active thromboembolic event
  • Severe liver disease (> child B)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00257179

Contact: Chong-Jen Yu, M.D., Ph.D. 886-2-2356-2905

National Taiwan University Hospital Recruiting
Taipei, Taiwan
Contact: Chong-Jen Yu, M.D., Ph.D.    886-2-2356-2905      
Sponsors and Collaborators
National Taiwan University Hospital
Principal Investigator: Chong-Jen Yu, M.D., Ph.D. National Taiwan University Hospital
  More Information Identifier: NCT00257179     History of Changes
Other Study ID Numbers: 9461700609
Study First Received: November 21, 2005
Last Updated: March 13, 2006

Keywords provided by National Taiwan University Hospital:
Tissue factor
Lung cancer
Tissue factor protein inhibitor
Factor VII
Factor X

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Coagulants processed this record on September 21, 2017